Who
Joshua T. Brumm
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Crescent Biopharma; CEO & President, Dyne Therapeutics; Officer, Kaleido Biosciences; COO and CFO, Versartis; EVP, Finance, Pharmacyclics; VP of Corporate Development, Zeltiq Aesthetics.
In numbers
- Trades disclosed
- 123
- Buys
- 1
- Sells
- 33
- Bought
- $25K
- Sold
- $29.3M
- Companies
- 6
- Companies where not an officer
- 0
- First trade
- 17 Feb 2012
- Last trade
- 18 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Sep 2026filed 18 Sep 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $131K7,837 at $16.71 | filing |
| 18 Sep 2026filed 18 Sep 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $131K7,837 at $16.71 | filing |
| 16 Sep 2026filed 18 Sep 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $29K1,610 at $17.90 | filing |
| 16 Sep 2026filed 18 Sep 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $29K1,610 at $17.90 | filing |
| 22 Jun 2026filed 23 Jun 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $761K42,305 at $17.99 | filing |
| 22 Jun 2026filed 23 Jun 2026 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Sold | $761K42,305 at $17.99 | filing |
| 15 Dec 2025filed 17 Dec 2025 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,467 at $0.00 | filing |
| 15 Dec 2025filed 17 Dec 2025 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Code A | —45,117 | filing |
| 15 Dec 2025filed 17 Dec 2025 | CBIO Crescent BiopharmaBiotechnology | SEC FORM 4 Code A | —10,000 | filing |
| 8 Dec 2025filed 10 Dec 2025 | CBIO Crescent Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —345,672 at $0.00 | filing |
| 11 Mar 2024filed 12 Mar 2024 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 11 Mar 2024filed 12 Mar 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code M | $277K50,000 at $5.54 | filing |
| 11 Mar 2024filed 12 Mar 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M40,072 at $25.42 | filing |
| 11 Mar 2024filed 12 Mar 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $259K9,928 at $26.10 | filing |
| 11 Mar 2024filed 12 Mar 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $203K7,769 at $26.12 | filing |
| 11 Mar 2024filed 12 Mar 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $223K8,618 at $25.93 | filing |
| 8 Mar 2024filed 12 Mar 2024 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —153,931 at $0.00 | filing |
| 8 Mar 2024filed 12 Mar 2024 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —209,412 at $0.00 | filing |
| 8 Mar 2024filed 12 Mar 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code M | $853K153,931 at $5.54 | filing |
| 8 Mar 2024filed 12 Mar 2024 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.2M209,412 at $5.54 | filing |
News
No headline names them, or the companies they trade most, lately.